Seeking Alpha

mk taylor

mk taylor
Send Message
View as an RSS Feed
View mk taylor's Comments BY TICKER:
Latest  |  Highest rated
  • Marketocracy Top 20 Manager, Nate Pile, Invested In MannKind And Afrezza [View article]
    Robert, Interesting to see bobdoc1 comments here also.
    The time factor to education is a calculation based on: 1. Number of prescribing physicians in the universe (target audience) In the case of Afrezza there is probably a primary target, and then a secondary target (with the necessity to stay within the indication at all costs!) 2. Number of reps in the field (reach) 3. Number of attempts to reach the target audience (frequency) Normally for a product launch (a big deal) - depending on the $ forecast - reach and frequency numbers will be increased by some factor. (All calculated to make the quarterly earnings be in line with guidance to the street.) In other words, additional reps being asked to "call on" targets more frequently. Once a month at least, most likely, depending on the geographic territory. Urban docs are easier to reach more frequently for example, than docs in Montana. If a rep gets into see the doc on the first try, (unlikely in reality) it will take a least two more visits to move their prescribing habits, UNLESS, patients start to report great results in big waves. I expect that five - six months would be a good result for training the primary target audience. So June, (as reported by bobdoc1) would fit this hypothesis. Hope that helps.
    Apr 23, 2015. 05:04 PM | 2 Likes Like |Link to Comment
  • Marketocracy Top 20 Manager, Nate Pile, Invested In MannKind And Afrezza [View article]
    Nate and Robert, thank you for the civilized discussion on MannKind. I've sold drugs earlier in my career and I may go find a Sanofi rep to see what they say. The reps will have a good feel for the reception by the doctors, who will be listening to and watching their patients. A drug rep loves to have a new product, especially if it is not another "me too" , which Afrezza certainly is not! Additionally, drug reps are paid on market share and new scripts, so they clearly want the marketing muscle of Sanofi to kick in. A drug like Afrezza, is different enough, that you want to train EVERYONE, sales and clinical alike, very well. Above all, you do not want an adverse event after launch due to some untrained person improperly using the drug. We are only in q2 of a new drug launch. This is something new and doctors and patients want to see how "others" do before they try Afrezza. Give it time. Afrezza is a game changer!
    Apr 23, 2015. 09:11 AM | 13 Likes Like |Link to Comment
  • A Close-Up Look At The Report That Had MannKind Investors Reeling [View article]
    Very helpful. Thanks.
    Mar 11, 2015. 10:43 AM | Likes Like |Link to Comment
  • Starbucks: Better Than McDonald's And Chipotle [View article]
    When I was in London the summer of 2011, Starbucks was everywhere. And the lines were not short. Then they said they were expanding by some large number of stores into Asia. I figured if England likes Starbucks this much, the Asian countries should as well. I bought at 40 something, and have not regretted it!
    Aug 2, 2013. 12:09 AM | 1 Like Like |Link to Comment